Breakthrough designation for Sage's PPD candidate

Sage Therapeutics Inc. (NASDAQ:SAGE) gained $4.45 (12%) to $40.92 on Tuesday after FDA granted breakthrough therapy designation to postpartum depression candidate SAGE-547. In July, Sage said SAGE-547 met the primary endpoint in a Phase II study to treat severe PPD (see BioCentury Extra, July 12). ...